ConductScience.org, home
Campath, Calcineurin Inhibitor Reduction and Chronic Allograft Nephropathy
API referenceFor AI assistants

Trial · NCT01120028

Adverse events104

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

1 to 20 of 104

Download this page as JSON
TypeEventOrgan systemGroupAffectedAt riskEvents
seriousBlood and lymphatic system disordersBlood and lymphatic system disordersPeriod 1: Alemtuzumab/Tacrolimus26426
seriousBlood and lymphatic system disordersBlood and lymphatic system disordersPeriod 1: Basiliximab/Tacrolimus15426
seriousBlood and lymphatic system disordersBlood and lymphatic system disordersPeriod 2: Sirolimus3197
seriousBlood and lymphatic system disordersBlood and lymphatic system disordersPeriod 2: Tacrolimus7197
seriousCardiac disordersCardiac disordersPeriod 1: Alemtuzumab/Tacrolimus14426
seriousCardiac disordersCardiac disordersPeriod 1: Basiliximab/Tacrolimus15426
seriousCardiac disordersCardiac disordersPeriod 2: Sirolimus10197
seriousCardiac disordersCardiac disordersPeriod 2: Tacrolimus3197
seriousCongenital, familial and genetic disordersCongenital, familial and genetic disordersPeriod 1: Alemtuzumab/Tacrolimus0426
seriousCongenital, familial and genetic disordersCongenital, familial and genetic disordersPeriod 1: Basiliximab/Tacrolimus0426
seriousCongenital, familial and genetic disordersCongenital, familial and genetic disordersPeriod 2: Sirolimus0197
seriousCongenital, familial and genetic disordersCongenital, familial and genetic disordersPeriod 2: Tacrolimus0197
seriousEar and labyrinth disordersEar and labyrinth disordersPeriod 1: Alemtuzumab/Tacrolimus1426
seriousEar and labyrinth disordersEar and labyrinth disordersPeriod 1: Basiliximab/Tacrolimus0426
seriousEar and labyrinth disordersEar and labyrinth disordersPeriod 2: Sirolimus0197
seriousEar and labyrinth disordersEar and labyrinth disordersPeriod 2: Tacrolimus0197
seriousEndocrine disordersEndocrine disordersPeriod 1: Alemtuzumab/Tacrolimus0426
seriousEndocrine disordersEndocrine disordersPeriod 1: Basiliximab/Tacrolimus0426
seriousEndocrine disordersEndocrine disordersPeriod 2: Sirolimus0197
seriousEndocrine disordersEndocrine disordersPeriod 2: Tacrolimus0197

Source ClinicalTrials.govtrials-2026-11-12-0.5.0

Next page

Sources 3

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
  • NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated
  • NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this list from software.

Twenty rows a page, as JSON. No key.

GET https://conductscience.org/api/trials/v1/NCT01120028/events

API referenceFor AI assistants